APLS250117C12500
- 31.50
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): When Will It Breakeven?
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Apellis Pharmaceuticals Price Target Announced at $36.00/Share by Goldman Sachs
Goldman Sachs Downgrades Apellis Pharmaceuticals(APLS.US) to Hold Rating
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) to a Hold
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Buy Rating for Apellis Pharmaceuticals: Promising Growth Potential of Syfovre in Geographic Atrophy Market
Worst Performing Stocks for Tax Loss Selling – Wolfe
Express News | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Fly 27% But Investors Aren't Buying For Growth
RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley
Morgan Stanley Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $31
Neutral Stance on Apellis Pharmaceuticals Amid Competitive Uncertainties and Market Stability
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Apellis Pharmaceuticals Up Nearly 16%, On Pace for Largest Percent Increase Since August 2023 -- Data Talk